Inhalerx Ltd (AU:IRX) — Market Cap & Net Worth
Market Cap & Net Worth: Inhalerx Ltd (IRX)
Inhalerx Ltd (AU:IRX) has a market capitalization of $4.18 Million (AU$5.91 Million) as of September 22, 2026. Listed on the AU stock exchange, this Australia-based company holds position #29021 globally and #1593 in its home market, demonstrating a 33.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inhalerx Ltd's stock price AU$0.02 by its total outstanding shares 246257323 (246.26 Million). Also see Inhalerx Ltd total assets for a full breakdown of the balance sheet.
Inhalerx Ltd Market Cap History: 2017 to 2026
Inhalerx Ltd's market capitalization history from 2017 to 2026. Data shows change from $23.68 Million to $4.18 Million (-25.92% CAGR). Also see IRX cash flow metrics for how efficiently the company converts equity into cash flow.
Inhalerx Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inhalerx Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check IRX stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
18.20x
Inhalerx Ltd's market cap is 18.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $23.68 Million | $493.31K | -$2.10 Million | 48.00x | N/A |
| 2018 | $10.14 Million | $345.79K | -$1.87 Million | 29.33x | N/A |
| 2019 | $5.75 Million | $46.60K | -$2.39 Million | 123.39x | N/A |
| 2020 | $13.42 Million | $97.50K | -$1.01 Million | 137.61x | N/A |
| 2021 | $15.68 Million | $167.30K | -$1.11 Million | 93.73x | N/A |
| 2022 | $10.45 Million | $24.80K | -$1.93 Million | 421.56x | N/A |
| 2023 | $5.05 Million | $1.20 Million | -$1.44 Million | 4.20x | N/A |
| 2024 | $6.10 Million | $335.10K | -$1.28 Million | 18.20x | N/A |
Competitor Companies of IRX by Market Capitalization
Companies near Inhalerx Ltd in the global market cap rankings as of September 22, 2026. Review Inhalerx Ltd (IRX) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Inhalerx Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $129.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #336 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $61.21 Billion USD ( AU$86.50 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #508 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.45 Billion | $510.72 |
| #336 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $798.17 |
| #455 | CSL Ltd | AU:CSL | $61.21 Billion | AU$178.30 |
| #508 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $172.94 |
Inhalerx Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Inhalerx Ltd's market cap moved from $23.68 Million to $ 4.18 Million, with a yearly change of -25.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$4.18 Million | 0.00% |
| 2025 | AU$4.18 Million | -31.43% |
| 2024 | AU$6.10 Million | +20.69% |
| 2023 | AU$5.05 Million | -51.67% |
| 2022 | AU$10.45 Million | -33.33% |
| 2021 | AU$15.68 Million | +16.88% |
| 2020 | AU$13.42 Million | +133.33% |
| 2019 | AU$5.75 Million | -43.30% |
| 2018 | AU$10.14 Million | -57.17% |
| 2017 | AU$23.68 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 22nd, 2026 the market cap of Inhalerx Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.18 Million USD |
| MoneyControl | $4.18 Million USD |
| MarketWatch | $4.18 Million USD |
| marketcap.company | $4.18 Million USD |
| Reuters | $4.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inhalerx Ltd
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexali… Read more